Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

Shanghai Pulse Medical Technology (PMT HK)

<ul>
<li>Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.</li>
<li>We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.</li>
<li>We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.</li>
</ul>


Shanghai Pulse is a leading player in the FFR assessment in China. The company is looking to raise up to USD 200 m via a Hong Kong listing.
We look at the company's key products QFR, OFR and UFR. We also provide our thoughts on the investment thesis.
We think the company has a decent investor backing and meanwhile we also highlight concerns on its management.


Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Insight Lifetech / Equity Capital Markets

<p>On August 18, 2021, <a href="https://www.smartkarma.com/entities/insight-lifetech-co-ltd" target="_blank" data-smartkarma-citation="entities:34278:1" rel="noopener">Insight Lifetech (ILT HK)</a> submitted its prospectus to the Hong Kong Stock Exchange and officially started its IPO process. Lifetech is a medtech company dedicated to developing precision solutions with the potential to transform the diagnosis and treatment of cardiovascular diseases. Founded more than five years ago, Lifetech had already gone through six rounds of financing (at least one round every year). This article mainly analyzed the industry characteristics, the business and the concerns of the Company.</p>

On August 18, 2021, Insight Lifetech (ILT HK) submitted its prospectus to the Hong Kong Stock Exchange and officially started its IPO process. Lifetech is a medtech company dedicated to developing precision solutions with the potential to transform the diagnosis and treatment of cardiovascular diseases. Founded more than five years ago, Lifetech had already gone through six rounds of financing (at least one round every year). This article mainly analyzed the industry characteristics, the business and the concerns of the Company.

Pre-IPO Insight Lifetech - Insights on Industry, Products and Concerns

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Insight Lifetech (ILT HK)

Shanghai Pulse Medical (博动医疗) Pre-IPO: Leading Image-Based FFR Player

Shanghai Pulse Medical is a leading player in the FFR assessment in China. We look at the product line of the company, including QFR, OFR and UFR.

Ke Yan, CFA, FRM

Pre-IPO Insight Lifetech - Insights on Industry, Products and Concerns

This article analyzed Insight Lifetech in terms of the industry characteristics of interventional cardiovascular devices, the products/candidates...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)